From biologicals to biosimilars
DOI:
https://doi.org/10.66344/jpad.26.1.2016.66References
Müller R, Renner C, Gabay C, Cassata G, Lohri A, Hasler P. The advent of biosimilars: challenges and risks. Swiss Med Wkly. 2014;144:w13980.
FDA Draft Guidance for Industry. Quality Considerations in Demonstrating Biosimilarity to a Reference Product, 2012.
European Medicines Agency. Biosimilar Medicines, 20052014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000318.jsp. Accessed September 29, 2014.
World Health Organization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Expert Committee on Biological Standardization. Geneva, Switzerland. October 19-23, 2009. Available at: http:// www.managedcaremag.com/archives/2014/Katherine T Adams/biosimilars-take-centre -stage
U.S. Food and Drug Administration. Guidance for industry: Scientific considerations in demonstrating biosimilarity to a reference product. 2012 Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed December 21, 2014.
Amgen Inc. Amgen 2004 Annual report. Available at: http://library.corporateir.net/library/61/616/61656/items/143940/amgn2004AR.pdf. Accessed December 21, 2014.
Rathore N. Rajan RS. Current perspectives on stability of protein drug products during formulations, fill and finish operations. Biotechnol Prog. 2008;24:504-14
Choy E, Allen Jacobs I. Biosimilar safety considerations in clinical practice. Semin Oncol. 2014;41(Suppl. 1):S3-S14.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
